Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Stahel on Treatment Sequencing in Stage IV NSCLC

May 3rd 2019

Rolf A. Stahel, MD, professor in the oncology clinic, University Hospital, Zurich, discusses treatment sequencing in stage IV non–small cell lung cancer.

Dr. Addeo Discusses the Need for Biomarkers in NSCLC

May 3rd 2019

Alfredo Addeo, MD, consultant medical oncologist, University Hospital of Geneva, discusses the need for effective biomarkers in non–small cell lung cancer.

Unanswered Questions With the Role of TMB in NSCLC

May 3rd 2019

Umberto Malapelle, PhD, assistant professor, University of Naples Federico II, discusses unanswered questions regarding the role of tumor mutational burden in non–small cell lung cancer.

Lung Cancer Summit Co-Chair Advocates for Interactive, Evidence-Based Discussions in Evolving Field

May 3rd 2019

Alfredo Addeo, MD, discusses the uniqueness of the 1-day Lung Cancer Summit and recent therapeutic advancements that have occurred in the lung cancer space.

Chemoimmunotherapy Combos Solidified as Frontline Standard in Nonsquamous NSCLC

May 3rd 2019

The rationale for frontline chemoimmunotherapy in stage IV nonsquamous non–small cell lung cancer, now made evident by several phase III trials, stems from its synergistic activity, stimulatory effects on neoantigens, and tolerable safety profile.

Dr. Nadler Discusses the IMpower131 Study in Squamous NSCLC

May 2nd 2019

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the IMpower131 study in squamous metastatic non–small cell lung cancer.

Minimizing Adverse Effects of Chemoradiotherapy

May 2nd 2019

Radiation Therapy: Dosing, Scheduling, & Toxicity Management

May 2nd 2019

Radiation Therapy Eligibility for Stage III NSCLC

May 2nd 2019

Radiation Options for Stage III NSCLC

May 2nd 2019

The Multidisciplinary Approach to Chemoradiotherapy

May 2nd 2019

The Changing Landscape in Molecular Testing

May 2nd 2019

PD-L1 Testing in Stage III NSCLC & General Education

May 2nd 2019

How the Treatment of Stage III NSCLC Has Changed

May 2nd 2019

Recommended Settings for Durvalumab Treatment

May 2nd 2019

Importance of PD-L1 Status in Treating Stage III NSCLC

May 2nd 2019

Impact of the PACIFIC Study Updated Analysis

May 2nd 2019

How Durvalumab Has Changed the Standard of Care

May 2nd 2019

Immunotherapy in Stage III NSCLC

May 2nd 2019

Assay Validation and Interdisciplinary Communication

May 2nd 2019